Stephen Knight

Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 30 years and invests broadly across healthcare. Steve serves on the Board of Directors of Aerium Therapeutics, Atalanta Therapeutics, Genomics plc, Leyden Labs, Paradigm, Quantum Circuits, Inc. (QCI) and Skyline Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Prime Medicine (NASDAQ: PRME), Proteostasis Therapeutics (NASDAQ: PTI), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA) and Semma Therapeutics (acquired by Vertex).